Advertisement
Singapore markets open in 5 hours 50 minutes

  • Straits Times Index

    3,348.87
    +12.28 (+0.37%)
     

  • S&P 500

    5,266.41
    -11.10 (-0.21%)
     

  • Dow

    38,461.80
    -224.52 (-0.58%)
     

  • Nasdaq

    16,752.19
    +17.17 (+0.10%)
     

  • Bitcoin USD

    69,149.80
    +1,457.55 (+2.15%)
     

  • CMC Crypto 200

    1,452.03
    -15.91 (-1.08%)
     

  • FTSE 100

    8,262.75
    -12.63 (-0.15%)
     

  • Gold

    2,368.60
    +22.80 (+0.97%)
     

  • Crude Oil

    74.14
    -2.85 (-3.70%)
     

  • 10-Yr Bond

    4.4020
    -0.1120 (-2.48%)
     

  • Nikkei

    38,923.03
    +435.13 (+1.13%)
     

  • Hang Seng

    18,403.04
    +323.43 (+1.79%)
     

  • FTSE Bursa Malaysia

    1,596.68
    -7.58 (-0.47%)
     

  • Jakarta Composite Index

    7,036.19
    +65.46 (+0.94%)
     

  • PSE Index

    6,470.74
    +37.64 (+0.59%)
     

GoodRx (GDRX) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2-min read

GoodRx Holdings, Inc. (GDRX) reported $197.88 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 7.6%. EPS of $0.08 for the same period compares to $0.07 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $196.2 million, representing a surprise of +0.86%. The company delivered an EPS surprise of -11.11%, with the consensus EPS estimate being $0.09.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how GoodRx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Monthly Active Consumers: 7 compared to the 7 average estimate based on three analysts.

  • Subscribers: 778 versus the two-analyst average estimate of 866.

  • Revenue- Prescription transactions: $145.40 million compared to the $145.51 million average estimate based on five analysts. The reported number represents a change of +7.8% year over year.

  • Revenue- Other: $5.38 million versus $4.89 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +19.4% change.

  • Revenue- Pharma Manufacturer Solutions: $24.51 million versus $23.21 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +20.1% change.

  • Revenue- Subscription: $22.60 million versus $22.56 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -6.2% change.

View all Key Company Metrics for GoodRx here>>>

Shares of GoodRx have returned +8.7% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research